User login
Key clinical point: Temporarily discontinuing endocrine therapy (ET) to attempt pregnancy did not increase the recurrence risk for breast cancer (BC) in young women with early hormone receptor-positive (HR+) BC.
Major finding: After a median follow-up of 41 months, 44 patients had BC and the incidence of BC events was not higher among patients who interrupted ET vs control individuals with BC from an external cohort who received treatment with different adjuvant endocrine strategies (hazard ratio 0.81; 95% CI 0.57-1.15). Pregnancy was reported by 368 patients and 317 patients had ≥1 live birth.
Study details: Findings are from a single-group trial including 516 premenopausal women aged ≤42 years with stage I, II, or III HR+ BC treated with ET for 18-30 months who discontinued ET to attempt pregnancy.
Disclosures: This study was supported by the ETOP IBCSG Partners Foundation and other sources. Some authors declared serving as consultants; receiving grants, contracts, or travel support; or having other ties with several sources.
Source: Partridge AH et al for the International Breast Cancer Study Group, and the POSITIVE Trial Collaborators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645-1656 (May 4). Doi: 10.1056/NEJMoa2212856
Key clinical point: Temporarily discontinuing endocrine therapy (ET) to attempt pregnancy did not increase the recurrence risk for breast cancer (BC) in young women with early hormone receptor-positive (HR+) BC.
Major finding: After a median follow-up of 41 months, 44 patients had BC and the incidence of BC events was not higher among patients who interrupted ET vs control individuals with BC from an external cohort who received treatment with different adjuvant endocrine strategies (hazard ratio 0.81; 95% CI 0.57-1.15). Pregnancy was reported by 368 patients and 317 patients had ≥1 live birth.
Study details: Findings are from a single-group trial including 516 premenopausal women aged ≤42 years with stage I, II, or III HR+ BC treated with ET for 18-30 months who discontinued ET to attempt pregnancy.
Disclosures: This study was supported by the ETOP IBCSG Partners Foundation and other sources. Some authors declared serving as consultants; receiving grants, contracts, or travel support; or having other ties with several sources.
Source: Partridge AH et al for the International Breast Cancer Study Group, and the POSITIVE Trial Collaborators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645-1656 (May 4). Doi: 10.1056/NEJMoa2212856
Key clinical point: Temporarily discontinuing endocrine therapy (ET) to attempt pregnancy did not increase the recurrence risk for breast cancer (BC) in young women with early hormone receptor-positive (HR+) BC.
Major finding: After a median follow-up of 41 months, 44 patients had BC and the incidence of BC events was not higher among patients who interrupted ET vs control individuals with BC from an external cohort who received treatment with different adjuvant endocrine strategies (hazard ratio 0.81; 95% CI 0.57-1.15). Pregnancy was reported by 368 patients and 317 patients had ≥1 live birth.
Study details: Findings are from a single-group trial including 516 premenopausal women aged ≤42 years with stage I, II, or III HR+ BC treated with ET for 18-30 months who discontinued ET to attempt pregnancy.
Disclosures: This study was supported by the ETOP IBCSG Partners Foundation and other sources. Some authors declared serving as consultants; receiving grants, contracts, or travel support; or having other ties with several sources.
Source: Partridge AH et al for the International Breast Cancer Study Group, and the POSITIVE Trial Collaborators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645-1656 (May 4). Doi: 10.1056/NEJMoa2212856